Embed Size (px)
Citation preview
Changing scalp cooling. Changing lives.Introducing DigniCap Delta®
The Next Generation in Scalp CoolingFDA cleared since 2015 to reduce chemotherapy induced alopecia, The DigniCap® Scalp Cooling System is the most effective scalp cooling device on the market.1
1JAMA Feb 14, 2017
DigniCap Delta Benefits:• Single patient unit for flexibility in tight spaces• Flexible dual cap system provides uniform
contact for optimal results• Comfortable cap fit with adjustable tabs and
chin strap• Solid state cooling provides precise
temperature control• Patient mobility for post-infusion cooling• Intuitive user interface for ease of operation• Quick connect hose positioned for
patient comfort• Ergonomic design for clinical staff
and patients• Quiet operation for minimal disruption
during treatment®
Clinically superior scalp cooling
Learn more now. Visit dignicap.com
What Is Scalp Cooling?Scalp cooling is a proven way to reduce hair loss from chemotherapy that has been used successfully by thousands of patients worldwide for several decades. In this treatment, the scalp is cooled while cytostatic drugs are being administered.
How Does Scalp Cooling Work?Two reactions occur during scalp cooling:
1. Reduced blood flowVasoconstriction in the scalp area limitsthe amount of chemotherapy agent delivered to the hair follicles.
2. Reduced metabolismLower scalp temperature decreases the reaction rate causing normal cellular activity in the localized scalp area to slow dramatically.
With these two reactions the follicles absorb fewer chemotherapeutic agents and alopecia is significantly reduced.
Why Is Scalp Cooling Important?A patient’s hair can be a major part of their identity, and many patients rate hair loss as one of the most devastating side effects of chemotherapy. Chemotherapy-induced hair loss is an unwelcome reminder of disease, one that can negatively affect self-image, confidence, overall sense of well-being and a patient’s attitude toward treatment.
Why is DigniCap Clinically Superior Scalp Cooling?Superior results in the pivotal trial for FDA clearance
• DigniCap achieved 66.3% success withtaxanes in the U.S. clinical trial.
• The competitor’s success rate wasjust 50.5% overall and 59%with taxanes in theirU.S. clinical trial.
Discover the DELTA Advantage:
• 54% smaller than previous device
• Up to 80% reduction in nursing time
• Improved patient comfort frominnovative thermoelectric cooling
• Quick connection
• Device portability
• Intuitive user interface
• Single patient cap system
• Flexible cooling wrap for precise fit
• Adjustable thermal cap to maintainclose contact
®
Clinically superior scalp cooling
PRO 20190809-01 EN
Learn more now. Visit dignicap.com
Reducedtemperature
Reducedblood flow
Reducedmetabolism
Reducedabsorption
Reducedhair loss
Minimize hair loss and maintain privacy, identity and control for patients with The DigniCap Scalp Cooling System
66.3% Kept theMajority of Their Hair
Results when observed a month after the last chemotherapy cycle.
In comparison, 100% in the control group that did not use DigniCap lost more than half of their hair.
